GlassScriptPhysician profile
Tasha S Mack
NPI 1184051336
$13,660.14
in general payments reported to CMS, 2019-2025
35 companies · $3,285 in 2025
The $3,285 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,587 · 2022: $2,401 · 2023: $2,850 · 2024: $3,537 · 2025: $3,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,196 · Education: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,195.73 |
| Education | $476.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,851.68 | 2021-2025 | |
| Janssen Biotech, INC. | $1,654.95 | 2021-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $1,452.86 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,413.23 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Leo Pharma INC. | $1,137.21 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $740.57 | 2021-2025 | Jublia, Siliq, Duobrii |
| Novartis Pharmaceuticals Corporation | $584.34 | 2021-2025 | |
| Pfizer INC. | $549.38 | 2021-2025 | |
| Incyte Corporation | $460.07 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $446.54 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $422.51 | 2021-2023 | Taltz, Olumiant |
| Ucb, INC. | $385.94 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $380.10 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $358.91 | 2021-2025 | |
| Amgen INC. | $356.89 | 2022-2025 | Otezla, Otezla |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $262.37 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $205.25 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $160.15 | 2023 | |
| Mayne Pharma Commercial LLC | $115.57 | 2023-2025 | |
| Botanix Sb INC | $105.23 | 2025 | Sofdra |
| Epi Health, LLC | $90.57 | 2021-2022 | |
| Biofrontera INC. | $72.40 | 2021-2022 | |
| Blueprint Medicines Corporation | $67.90 | 2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.55 | 2023 | Cyltezo, Spevigo |
| Organon LLC | $57.85 | 2025 | Vtama, Nexplanon |
| Genentech USA, INC. | $55.57 | 2025 | Xolair |
| Kyowa Kirin, INC. | $52.26 | 2022-2025 | |
| Almirall LLC | $27.97 | 2022-2024 | Seysara |
| Biocon Biologics INC | $22.51 | 2024 | Hulio |
| Biowound Solutions, INC. | $21.90 | 2025 | Bio-Connekt |
| Allergan, INC. | $21.21 | 2022 | |
| Fresenius Kabi USA, LLC | $20.21 | 2023 | |
| Boston Scientific Corporation | $19.01 | 2021 | |
| Vyne Pharmaceuticals INC. | $13.31 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasha Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.